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The DNA polymerases and thymidine kinases in- 
duced  by  three  drug-resistant  mutants  of herpes sim- 
plex virus type 1 (Sl, Tr7, and  B3)  and  their  common 
parent strain, SC16, have  been  purified  and  their  prop- 
erties compared. No significant differences  were seen 
in  the affinities of  the  polymerases  for TTP and dGTP, 
or  for  the  triphosphates  of 9-(2-hydroxyethyloxy- 
methy1)guanine  (acyclovir)  or (~-5-(2-bromovinyl)-2’- 
deoxyuridine  (BVdU)  (drugs  used in their isolation). In 
contrast  all  three  mutants  induced  abnormal  thymidine 
kinases. Those  induced by the acyclovir-resistant mu- 
tants, S1 and Tr7, showed  reduced affinities for  thymi- 
dine,  acyclovir,  and also BVdU.  Thymidine kinase in- 
duced by the BVdU-resistant mutant B3 showed re- 
duced  affinity  for BVdU, but its affinities for  thymidine 
and acyclovir were similar to those of the wild type 
enzyme.  Thus, it appears  that these variants of herpes 
simplex virus express altered  thymidine kinases with 
impaired ability to phosphorylate  particular  nucleoside 
analogue  drugs  and these characteristics probably  ac- 
count  for  the  drug resistance of the viruses. This strat- 
egy for resistance is important as it may result in 
variants  with  undiminished pathogenicity. 
Many nucleoside analogues inhibit replication of herpes 
simplex virus (for review see Refs. 1 and 2) and the most 
effective of them  appear  to  share a common mechanism of 
action involving activities of two virus-coded enzymes, thy- 
midine kinase and DNA polymerase. It is the triphosphate 
derivatives of these drugs which interact with virus-specific 
DNA polymerase to disrupt DNA synthesis (3-7). However, 
Significant activation to  the triphosphate can only occur in 
infected cells as  the first stage  in this process, formation of 
the monophosphate, is performed by virus-specific thymidine 
kinase (3, 8-10). 
The involvement of these two separate virus-coded func- 
tions in the action of these compounds is c o n f i i e d  by the 
observation that  the virus can  acquire resistance to them by 
mutation at  either genetic locus. This  has been demonstrated 
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with viruses resistant  to the drug 9-(2-hydroxyethoxy- 
methy1)guanine) (11-13). Most  resistant isolates of HSV‘ ob- 
tained following growth of virus in the presence of this drug 
fail to induce significant levels of thymidine kinase (12-14). 
Such  mutants, with a TK- phenotype, are viable only because 
thymidine kinase is a nonessential virus function in most 
tissue culture systems (15, 16), and many  reports  have now 
shown that these mutants lack pathogenicity when tested  in 
animals (17-20). Mutants with alterations in  DNA polymerase 
appear  to arise with much lower frequency but this may be 
explained by the constraints on mutation in that gene. Unlike 
thymidine kinase, DNA polymerase is essential for virus rep- 
lication and for virus to be viable a mutant DNA polymerase 
must be capable of performing its normal functions. 
Although most acyclovir-resistant mutants fail to express 
thymidine kinase we have recently shown that more subtle 
changes in this enzyme, analogous to  the  substrate specificity 
changes observed with DNA polymerase, may confer resist- 
ance (21, 22). These observations have suggested a further 
strategy by which HSV can acquire resistance to nucleoside 
analogues and yet maintain a TK’ phenotype, a strategy 
which may be particularly important since these viruses, 
unlike TK- variants,  appear  to  retain pathogenicity (18, 21). 
In this  paper we describe detailed studies  on the purified 
DNA polymerases and thymidine kinases induced by three 
pathogenic drug-resistant viruses isolated from the same par- 
ent HSV-1 strain (SC16). We show in each case that resistance 
is due to expression of altered thymidine kinase, and the 
implications of this finding are discussed in relation to the 
normal function of this enzyme. 
MATERIALS AND METHODS 
Cells and Tissue Culture-The cells used were baby hamster 
kidney cells BHK-21); BUdR-resistant BHK cells,  which express no 
cellular thymidine kinase; and BHK TK1 cells,  which  were made by 
biochemical transformation of BU-BHK cells to TK’ phenotype by 
the calcium phosphate precipitation method (23) using the DNA 
plasmid, px-1 (24) containing the cloned HSV-1 TK gene.  Cells  were 
maintained in Glasgow-modified  Eagle’s medium supplemented with 
10%  calf serum and 10% tryptose phosphate  broth. 
Viruses-SC16, an HSV-1 strain (25), and drug-resistant mutants 
made from it were  used in this  study. The isolation of the acyclovir- 
resistant mutant E 1 6  S1 has been described (21). SC16 Tr7,  another 
’ The abbreviations and trivial names used are: HSV, herpes sim- 
plex virus; HSV-I, HSV, type 1; acyclovir, 9-(2-hydroxyethoxy- 
methy1)guanine; BVdU, (E)-5-(2-bromovinyl)-2”deoxyuridine; acy- 
clo-GTP, 9-(2-hydroxyethoxymethyl)guanine triphosphate; SDS, so- 
dium dodecyl sulfate; S1, HSV-1 strain sC16 S1; Tr7, HSV-1 strain 
SC16 Tr7; B3, HSV-1 strain SC16  B3. 
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acyclovir-resistant  virus, was isolated  in BHK  TK1 cells infected  with 
SC16 in the presence of 4 PM acyclovir. SC16 B3, a BVdU-resistant 
mutant, was made by infecting BHK cells with SC16 in the presence 
of 30 p~ BVdU (26). This  mutant was kindly provided by  Dr.  H. J. 
Field, Department of Pathology,  Cambridge  University,  United King- 
don. 
Viruses were cloned and  stocks were prepared  in BHK cells using 
low multiplicity infections. 
Measurement of Virus Sensitivity to Acyclovir and BVdU- 
Plaque reduction  assays were performed using BHK monolayers as 
described previously (27). 
Virus Infection of BU-BHK Cells for Enzyme Preparations- 
Confluent  monolayers of BU-BHK cells (about 2 X 10") were infected 
a t  a  multiplicity of 10 plaque-forming  units/cell.  Infection was allowed 
to proceed for I8 h, after which the cells were harvested into the 
medium,  pelleted, and frozen at  -70  "C until required. 
Measurement of Thymidine  Kinase  Induced  in  Infected Cells- 
BU-BHK cells were infected and assayed for thymidine  kinase  activ- 
ity  as described previously (22). 
Extraction and  Purification of Virus DNA Polymerase and  Thy- 
midine Kinase-The purification procedure used was designed to 
permit purification of both HSV DNA polymerase and thymidine 
kinase from the  same infected cell extract. 
All buffers (except those used for thymidine  kinase affinity column 
chromatography) contained,  in addition  to  the indicated amount of 
potassium phosphate buffer, pH 7.5,2 mM dithiothreitol, 1 mM EDTA, 
1 mM phenylmethylsulfonyl fluoride, 50 p~  thymidine, and 20% 
glycerol. All steps were  performed at 4 "C. Infected cell pellets were 
thawed and resuspended in 4 volumes of extraction buffer containing 
250 mM potassium phosphate buffer, pH 7.5. Following disruption  by 
ultrasonic  vibration, the sonicate was centrifuged at  15.000 rpm  in  a 
Sorvall  RC-2B rotor for 30 min. The  supernatant was passed through 
a DEAE-cellulose column, equilibrated with extraction buffer to 
remove nucleic acids. The flow through was collected and diluted to 
a  concentration of 50 mM potassium phosphate buffer, pH 7.5 then 
applied to a second DEAE-cellulose column, equilibrated with 50 mM 
potassium phosphate buffer, pH 7.5. Thymidine kinase was recovered 
in the column flow through  and HSV  DNA  polymerase activity was 
eluted with 250 m~ potassium phosphate buffer, pH 7.5. HSV DNA 
polymerase was further purified through phospho- and DNA-cellulose 
columns as previously described  (28). 
Fractions containing thymidine kinase activity from the secoQd 
DEAE-cellulose  column were pooled and solid ammonium sulfate was 
added to 60%> saturation. The precipitate formed was collected by 
centrifugation, dissolved in 3 ml of thymidine kinase affinity column 
buffer A (0.05 M Tris-HCI, pH 7.5,  2 mM dithiothreitol, and 10% 
glycerol) and applied to a thymidine-Sepharose affinity column  equil- 
ibrated with buffer A. A  sequence of elution buffers (all  containing  2 
mM dithiothreitol, 10% glycerol, increasing concentrations of Tris- 
HCI, pH 7.5, and  thymidine) were applied to  the affinity column and 
thymidine kinase was eluted with a linear gradient of thymidine 
(100-300 p ~ ) ,  Tris-HCI, pH 7.5 (0.2-0.3 M), and KC1  (0-1.2 M).  Peak 
thymidine kinase fractions were pooled, glycerol and bovine serum 
albumin were added  as stabilizers to 30% and 0.5 mg/ml,  respectively, 
and  the fractions were stored  at -20 "C. Enzyme preparations were 
desalted by Sephadex (3-25 fitration prior to use. 
Enzyme  Assays-Thymidine  kinase  was  assayed at  37 "C  essen- 
tially as described by Klemperer et al. (29) using [I4C]thymidine as 
substrate a t  30 p~ (1.6 pCi/ml).  However, the  reaction mixture  with 
purified thymidine  kinase  also  contained  2 mM dithiothreitol  and 0.5 
mg/ml of bovine serum albumin, in addition to 5 mM ATP, 5 mM 
MgCI,, and 0.02 M sodium phosphate buffer, pH 6. When  thymidine 
was replaced by alternative  substrates  the following concentrations 
were used [14C]acyclovir, 500 p~ (6.2 pCi/ml) and ["HIBVdU, 42 pM 
(10 ,uCi/ml). A unit of thymidine kinase activity is defined as  the 
amount of enzyme catalyzing the conversion of 1 pmol of substrate/ 
min at  37 "C under the reaction  conditions  described. 
DNA polymerase assays were performed at 37 "C essentially as 
described by Ostrander  and Cheng  (28). Standard HSV DNA polym- 
erase  reaction  mixtures (0.1 m l )  contained 50 mM Tris-HC1, pH 8.0, 
200 mM KC1,4 mM MgCI?, 0.5 mM dithiothreitol, 0.2 mg/ml of bovine 
serum albumin, 12.5  pg of activated calf thymus  DNA,  made by the 
method of Baril et  al. (30), 0.1 mM each of dATP,  dGTP,  and  dCTP 
and 5 PM ["NITTP (2.5 pCi/ml).  When K, values  for  acyclo-GTP  were 
determined,  [JHITTP was replaced  in the  reaction mixture by [3H] 
dGTP  and cold TTP  (a t  0.1 mM) was added. A unit of DNA polym- 
erase activity is defined as the amount of enzyme catalyzing the 
incorporation of 1 pmol of TMP or dGMP/min at  37 "C under the 
reaction  conditions described. 
Radiolabeled substrates were obtained from the Radiochemical 
Centre,  Amersham,  United Kingdom, except ['4C]acyclovir and ["HI 
BVdU which were gifts from Dr. G. B. Elion, Burroughs Wellcome 
Co., Research  Triangle Park, NC, and  Dr.  E.  De Clercq, Rega Institute 
for Medical Research, Katholieke  Universiteit,  Leuven, Belgium, 
respectively. 
from Dr. Elion, Burroughs Wellcome Co.; BVdU from Dr. De Clercq, 
Antiviral Compounds-The following drugs were gifts: acyclovir 
Rega Institute; acyclo-GTP and  BVdUTP were prepared according 
60 the procedure of Ruth  and Cheng (7). 
SDS-Polyacrylamide  Gel Electrophoresis-Protein  samples were 
precipitated with 7% trichloroacetic acid overnight a t  4 "C and 
resuspended  in SDS gel sample buffer (0.1 M dithiothreitol, 2470 SDS, 
24 mM Tris-HC1, pH 6.8, 20% glycerol, 0.2% bromphenol blue).  Sam- 
ples were loaded onto a 3% polyacrylamide  stacking gel and  separated 
on a 15% polyacrylamide gel as described previously (22). Following 
electrophoresis the gels were fixed in 50% methanol, 12% acetic acid, 
washed in 10% ethanol, 5% acetic acid to remove excess SDS, and 
silver-stained by the  method of Merril  et al. (31). 
Protein Concentration Estimations-Protein concentration was 
estimated by the  method of Bradford (32). 
RESULTS 
Resistance to Antiviral Drugs-The sensitivities of the 
three  drug-resistant  mutants of HSV-1  to  both acyclovir and 
BVdU are shown  in Table I. All three  mutants were resistant 
to  the  drug used in  their isolation, showing EDw values at  
least 100-fold higher  than  those  obtained  with wild type virus. 
The acyclovir-resistant mutants, S1 and Tr7, also showed 
some  cross-resistance to BVdU although  the  BVdU-resistant 
mutant, B3, showed no resistance to acyclovir (26). Also 
included  in Table I are  data showing the level of thymidine 
kinase  induced by these viruses  assessed following high mul- 
tiplicity infection of BU-BHK cells. Tr7 and B3 induced 
similar levels to wild type enzyme but S1 induced approxi- 
mately 30% (22). 
Previous  experiments  on  thymidine kinase induced by the 
mutant S1 using crude enzyme preparations  had shown it  to 
have  many  properties which  distinguish it  from  the wild type 
enzyme. However, although the changed properties of thy- 
midine  kinase probably  account for the acyclovir resistance of 
this  mutant, we had  not directly  excluded the possibility of an 
additional  change in DNA polymerase (21, 22). Similarly, our 
TABLE I 
Virus sensitivities to acyclovir and  BVdU  and thymidine kinase 
induction  in infected  cells 
EDQ Thymidine  kinase 
Virus Acyclovir BVdU 
PM 
activityb 
SC16 0.10 0.03 100 
SI 10 0.54 30 
B3 0.05' 30' 110 
Tr7 22 0.37 130 
The sensitivity of viruses to acyclovir and BVdU was determined 
by plaque  reduction  in BHK cells. Preformed cell monolayers were 
infected with 100-250 plaque-forming units of virus and different 
concentrations of inhibitor  added. Plaques were allowed to develop 
for 2-3 days and  the cells were then fixed and stained.  A plot of the 
reduction  in  plaque  number (relative  to  no  drug  control)  against  drug 
concentration was constructed  and  the dose  required  for 50% plaque 
reduction (ED,) was obtained  from  the  graph. 
mined as described previously (22). BU-BHK cells were infected  with 
Thymidine kinase activity induced in infected cells was deter- 
virus a t  high multiplicity and  harvested  after 18 h. Cells were resus- 
pended at  3 X lo7 cells/ml in 0.01 ml of Tris-HC1, pH 7.4, sonicated, 
and centrifuged a t  100,000 X g for 45 min. The supernatant was 
assayed  for  thymidine  kinase  activity, which is expressed in the  table 
as a  percentage of that induced by SC16. 
Taken from Field and Neden (26). 
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FIG. 1. Elution profiles of HSV DNA polymerases and thymidine kinases from affinity columns. 
Infected cell extracts, prepared  as described under "Materials and Methods," were passed through two DEAE- 
cellulose columns (equilibrated with 250 pM and 50 mM phosphate buffer, pH 7.5, respectively) and HSV DNA 
polymerase and thymidine kinase were further purified by affinity column chromatography. A, material eluted in 
the flow through from the second DEAE-cellulose column (with  a  phosphate buffer concentration of 50 JLM) was 
pooled and ammonium sulfate was added to 60% saturation. The precipitate was resuspended in buffer A and 
applied to a thymidine-Sepharose affinity column (equilibrated with buffer A). The column was washed with 
increasing concentrations of Tris-HCI, pH 7.5, thymidine (dThd) and KC1 (addition of buffers is indicated by 
arrows) and thymidine kinase was eluted with a gradient of buffers B and F, i.e. KC1  (0-1.2 M), Tris-HCI, pH 7.5 
(0.2-0.3 M), and thymidine (100-300 pM). All elution buffers contained 2 mM dithiothreitol  and 10% glycerol; in 
addition, buffer B contained 0.2 M Tris-HC1, pH 7.5, and 100 p~ thymidine and buffer F contained 0.3 M Tris-HCI, 
pH 7.5,  1.2 M KCI, and 300 JLM thymidine. The amount of thymidine kinase activity loaded onto each column was: 
a, SC16 = 7.8 X lo4 units; b, S1 = 7.14 X 10j units; c, B3 = 6.9 X lo4 units; and d, Tr7 = 2.4 X lo5 units. 8, material 
eluted from the second DEAE-column with 250 mM phosphate buffer, pH 7.5,  was  pooled and dialyzed overnight 
to reduce the phosphate concentration to 100 mM. This was applied to a phosphocellulose column (equilibrated 
with 100 mM phosphate buffer, pH 7.5), DNA polymerase was eluted with a  phosphate gradient (0.1-0.5 M), and 
the peak HSV DNA polymerase fractions were pooled and applied to a DNA cellulose column (equilibrated with 
100 mM phosphate  buffer,  pH 7.5). DNA polymerase was eluted  from  this column with a  phosphate gradient (0.1- 
0.8 M). All buffers contained, in addition to potassium phosphate buffer, pH 7.5; 2 mM dithiothreitol, 1 mM EDTA, 
1 mM phenylmethylsulfonyl fluoride, and 20% glycerol. The amount of DNA polymerase activity loaded onto the 
DNA-cellulose column was: a, SC16 = 1.35 X lo4 units; b, SI = 1.6 X lo4 units; c, B3 = 5.6 X IO3 units; d, Tr7 = 3.6 
X IO" units. 
preliminary  experiments with thymidine kinases induced  by DNA polymerases and furthermore these experiments had 
Tr7  and B3 had also indicated changes  in those enzymes,2 but also been carried out with crude enzyme preparations. We 
we  had  not investigated the properties of the virus-specified therefore  purified both the thymidine  kinase and DNA polym- 
erase induced by each mutant and the wild type virus and 
' B. A. Larder and G. Darby, unpublished results. investigated the properties of the purified enzymes. 
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FIG. 2. SDS-polyacrylamide gel electrophoresis of proteins 
at different stages of thymidine kinase purification. Protein was 
precipitated from samples with 7% trichloroacetic acid at  4 "C over- 
night, resuspended in SDS gel sample buffer, and separated  on  a 15% 
polyacrylamide gel.  Following electrophoresis, the proteins were fixed 
in the gel and silver-stained by the method of Merril et al. (31). 1st 
DEAE, pooled flow through recovered from the fvst DEAE-cellulose 
column (2 pg of protein was loadedhact), 2nd DEAE, pooled flow 
through recovered from the second DEAE-cellulose column (1.5 pg  of 
protein loaded/tract). Affinity, pooled peak thymidine kinase frac- 
tions from the thymidine afinity column (0.4 pg of protein loaded/ 
tract). a, SC16 6, S1; C, B3; d, Tr7. It was estimated that  the pooled 
material from the first DEAE-cellulose columns contained 49% of 
total protein, the pooled material from the second DEAE-cellulose 
columns 3.4%, and the pooled peak thymidine kinase fractions 0.1% 
of total protein. 
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Purification of Enzymes-The purification scheme was 
designed to allow us to isolate the virus-induced DNA polym- 
erase and thymidine kinase from the same infected cell ex- 
tract. It was a combination of protocols described previously 
for wild type enzymes and resulted in similar yields and 
degrees of purification to those reported earlier for each 
procedure used independently (28,33). The final stage in the 
purifkation of each enzyme was affinity column chromatog- 
raphy. The elution profiles from these columns are shown in 
Fig.  1. The yields and specific activities of the  mutant enzymes 
were similar to those obtained with wild type enzyme. It was 
noticeable that although the DNA polymerase eluted from 
the DNA cellulose columns at  similar salt concentrations 
there were apparent differences in the elution profiles of the 
thymidine kinases from thymidine-Sepharose columns, with 
S1 eluting earlier, and B3 and Tr7 later  than wild type enzyme. 
We have previously shown that this purification scheme 
resulted in DNA polymerase preparations containing two 
specific major polypeptide species, revealed by silver staining 
following electrophoresis in SDS-polyacrylamide gels (34). A 
similar approach was  used to examine the purified thymidine 
kinase preparations as  the purity of thymidine kinase follow- 
ing affinity column chromatography has  not been previously 
established. In each case a single major polypeptide species 
was observed (Fig. 2) with M ,  = -45,000. This was similar in 
sue  to  the thymidine kinase subunit identified in extracts of 
"'S-labeled HSV-1-infected cells (35-37). 
Identification of Resistant Functions-As indicated above, 
studies with crude extracts of thymidine kinase induced by 
the  mutant S1 had shown that  this enzyme had  a changed 
substrate specificity. This was revealed in kinetic studies using 
crude enzyme preparations in which it was shown that  the 
enzyme had a higher K,,, (thus, decreased affinity) for the 
natural  substrate thymidine and  a loss of ability to bind the 
analogue acyclovir (22). Similar approaches have been used 
to show that  the DNA polymerase induced by acyclovir and 
phosphonoformic acid-resistant  mutants have altered affini- 
ties for acyclo-GTP or phosphonoformic acid compared to 
wild type enzyme (34, 38). We therefore examined the prop- 
erties of the enzymes induced by the three drug-resistant 
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FIG. 3. Inhibition of thymidine phosphorylation by acyclovir (ACV). Reaction rates were determined a t  
different concentrations of thymidine and two fixed concentrations of acyclovir. (ATP-Mg2+  concentration was 
kept constant a t  5 mM.) Lineweaver-Burk plots are shown. Amount of acyclovir in the reaction mixture; A ,  SC16 
thymidine kinase, no acyclovir (O), 0.25 mM acyclovir (A), 0.5 mM acyclovir (m; B, S1 thymidine kinase, no 
acyclovir (e), 1.18 mM acyclovir (A), 1.88 mM acyclovir (m); C, B3 thymidine kinase, no acyclovir (0). 0.25 mM 
acyclovir (A), 0.5 mM acyclovir (m); D, Tr7 thymidine kinase, no acyclovir (e), 1.18 mM acyclovir (A), 1.88 mM 
acyclovir (W). K,  values were evaluated from the replots of apparent K,,, versus acyclovir concentration (showed in 
insets). S, concentration of thymidine (micromolar) in the reaction mixture; V, picomoles of thymidine phospho- 
rylated/min/ml of enzyme. 
viruses,  looking particularly for a decrease in ability of thy- 
midine kinases to bind either the natural  substrate thymidine 
or its analogues, or impaired ability of DNA polymerases to 
recognize t~phosphates or t~phosphate analogues. 
The affinities of the thymidine kinases for thymidine were 
assessed by measuring the  Michae1~-Menten constants (K,,, 
values) using thymid~ne  as ubstrate and their affinities for 
acyclovir and BVdU  by measuring the inhibition of thymidine 
phosphory~ation by the appropriate analogues (Figs. 3 and 4). 
A similar approach was  used to measure the K,  values for 
dCTP and TTP of the purified DNA polymerases and also 
the Ki values for acyclo-GTP and BVdU-triphosphate using 
dGTP and TTP as substrates, respectively. The data are 
summarized in Table 11. Essentially the RNA polymerase 
purified  from mutant and wild type infected cells  showed no 
differences in K ,  or Kc values  the values obtained were similar 
to those in earlier reports  for HSV-1 DNA polymerase (5-7). 
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In contrast, significant differences were  observed between the 
mutant  and wild type thymidine kinases. The K,, values for 
thymidine of the thymidine kinases induced by the acyclovir- 
resistant mutants  Tr7  and Sl(2.5 and 10 p ~ )  were  10- and 50- 
fold higher, respectively, than that observed for the wild type 
enzyme. Similarly the Ki values of the mutant enzymes  for 
acyclovir  were increased by approximately 10-fold compared 
to wild type enzyme. The thymidine kinase induced by the 
BVdU-resistant mutant B3  showed little difference in K ,  for 
thymidine (K ,  0.3 p~ compared with K, for thymidine for 
the wild type enzyme of 0.2 p ~ ) .  However, the ability of BVdU 
to inhibit phosphorylation of thymidine by the  mutant en- 
zyme tKi 4.5 ppn) was considerably reduced (Ki for wild type 
enzyme 0.1 PM) suggesting that B3 thymidine kinase bound 
BVdU less strongly than SC16 thymidine kinase. Since the 
inhibition seen in each case was competitive, it is reasonable 
to assume that acyclovir and BVdU are alternative substrates 
-1 .. i 2 
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FIG. 4. Inhibition of thymidine  phosphorylation  by BVdU. Lineweaver-Burk plots are shown; these were 
constructed in a similar way to that described in the legend to Fig. 3, except that BVdU  was  used as the inhibitor 
instead of acyclovir. Amount of  BVdU in the reaction mixture; A, SCl6 thymidine kinase, no BVdU (e), 0.15 FRS 
BVdU (A), 0.3 PM BVdU (a); 8, S1 thymidine kinase, no BVdU (e), 3.5 p d  BVdU (A), 7 PM BVdU (a); C, B3 
thymidine kinase, no BVdU (e), 3 BVdU (A), 6 PM BVdU (=I; D, Tr7 thymidine kinase, no BVdU (e), 1.5 PM 
BVdU (A), 3 CM BVdU (R). K, values were evaluated from the replots shown in  insets  (apparent K, versus BVdU 
concentrations). S, concentration of thymidine (micromolar) in the reaction mixture; V, a picomoles of thymidine 
phosphorylated/min/d of enzyme. 
TABLE 11
Kinetic constants  for DNA polymerase and thymidine kinase  purified from wild type and  drug-resistant HSV- 
infected cells 
DNA polymerase and thymidine kinase were purified from either  parental (SCl6) or drug-resistant mutant virus 
infected cells as described under  “Materials  and Methods.” Reaction velocities were measured at  different substrate 
concentrations (TTP and dGTP for DNA polymerase and thymidine for thymidine kinase) and K,,, values were 
evaluated from Lineweaver-Burk plots. Ki values were determined by measuring reaction velocities in the presence 
and absence of fued concentrations of inhibitor. Inhibition of DNA polymerase by BVdU triphosphate was 
measured with limiting concentrations of [’HITTP and  saturating levels of dGTP, dATP,  and  dCTP. Inhibition by 
acyclo-GTP was measured using limiting concentrations of r3H]dGTP and saturating concentrations of TTP, 
dATP, and  dCTP. All kinetic constants  for thymidine kinase were determined at fixed, saturating levels of ATP- 
Mg2+ (5 m). - 




K ,  
0.68 0.62 0.70 0.68 1 Thymidine 0.2 10 0.3 2.5 
0.67 0.67 0.67 0.67 
BVdU-triphosphate 0.25 0.28 0.23  0.23 
I Acyclo-GTP 0.015  0.017 0.013 0.013 - 
0.1 5 4.5 1.5 
200 2200  225  2500 
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TABLE I11 
Relativephosphorylation  rates of thymidine, ACV, and BVdU by 
SC16 and mutant virus thymidine kinase 
Substrate 
Phosphorylation relative to thymidine" 
SC16 SI B3 Tr7 
% 
Thymidine 100 100 100 
ACV 
100 
39 NPh 42 NP 
BVdU 120 129 30 145 
a Phosphorylation  activity of thymidine  kinase purified from SC16 
and  mutant  virus-infected cells was measured using  different  radio- 
labeled substrates. The standard thymidine kinase assay reaction 
mixture  (described  under  "Materials  and  Methods")  containing  either 
thymidine (30 PM), acyclovir (500 p M ) ,  or  BVdU (42 CUM) as substrate 
was used. Reaction velocities are expressed as a percentage of the 
thymidine  phosphorylating rate for each enzyme. 
No phosphorylation  measurable;  levels  therefore less than 1%. 
for these enzymes and  this was subsequently confirmed (see 
below). 
Phosphorylation of Nucleoside Analogue  Substrates-The 
purified thymidine kinases were directly tested for ability to 
phosphorylate radiolabeled acyclovir or BVdU as substrate, 
and  this was compared in each case with the ability of the 
enzyme to phosphorylate thymidine. The results of these 
experiments are shown in Table 111. As expected acyclovir 
was phosphorylated by SC16 thymidine kinase but  to a lesser 
extent than thymidine or BVdU. At the concentration of 
acyclovir used in the assays (500 p ~ )  no phosphorylation of 
acyclovir by S1 and Tr7 thymidine kinases was observed, 
which is consistent with earlier  results using crude infected 
extracts (22).  
All enzymes except B3 thymidine kinase phosphorylated 
BVdU with slightly greater efficiency than thymidine itself. 
The poor phosphorylation of this substrate by B3 thymidine 
kinase cannot, be explained solely on the basis of the elevated 
Ki since the activity was determined at high substrate concen- 
tration (42 p ~ ) .  There may also be  a significant decrease in 
Vmax for phosphorylation of BVdU although we have not 
attempted to measure this  parameter directly since it is  ex- 
tremely difficult to measure absolute concentrations of en- 
zymes. 
DISCUSSION 
The advent of effective and selective drugs for use against 
herpes infections (e.g. acyclovir and BVdU) has drawn atten- 
tion to the potential problems posed by drug-resistant viruses. 
Although it is not yet clear how serious the  threat may be, 
there  are already reports that resistance is a problem confront- 
ing clinicians (39-41). In view  of this we felt it worthwhile to 
investigate virus phenotypes which might exhibit resistance, 
particularly those with similar pathogenicity to  the parent. 
In this paper we have focused on three pathogenic TK' 
drug-resistant mutants derived from the same HSV-1 parental 
strain. Two had been derived by growth of virus in the 
presence of acyclovir (21) and  the third by growth in  BVdU 
(26). Initial  studies indicated that all three  mutants induced 
TK, B3 and Tr7 inducing levels similar to  that of wild type 
enzyme and S1 inducing only about 30%. When tested for 
resistance to the drugs used in their selection, the  mutants 
were all considerably less sensitive than  their  parental strain. 
Tr7 and S1 were somewhat resistant to BVdU although the 
results obtained with S1 were variable. Significantly, the 
BVdU-resistant mutant B3 showed no cross-resistance to 
acyclovir (26). 
Previous work with S1 had shown it  to be pathogenic in  a 
mouse model system and  the infection was not affected by 
treatment with acyclovir (21). Similar  results  have been ob- 
tained with Tr7,3 and B3 also appears to be pathogenic, 
infection with this latter  mutant being refractory to  treatment 
with BVdU but not acyclovir (26). 
Thymidine kinase and DNA polymerase induced by each 
mutant were isolated and purified. Biochemical studies were 
then undertaken  to investigate whether  any of the enzymes 
induced had  altered  properties which might account for the 
resistance of the viruses to  the drugs. Results with the DNA 
polymerase suggested that these enzymes were similar if not 
identical to  the wild type enzyme. The K,,, values measured 
using TTP as substrate for each enzyme were not significantly 
different nor were the values obtained using dGTP. Similarly 
the K, values for acyclo-GTP were similar for each enzyme as 
were the KL values for BVdU triphosphate. There was thus no 
evidence that any of the DNA polymerases induced by the 
drug-resistant  variants differed from the wild type enzyme in 
their recognition of nucleoside triphosphates or their ana- 
logues. 
In contrast to  the results with DNA polymerases, the  thy- 
midine kinases induced by the  mutants  had properties which 
clearly distinguished them from the wild type enzyme. The 
K,,, values for thymidine of S1 and Tr7 thymidine kinases 
were considerably higher, indicating lower affinities for the 
natural  substrate.  The weakened binding was also reflected in 
the K, values for acyclovir. The K ,  for acyclovir of the wild 
type enzyme was 200 PM, but  both  mutant enzymes had K ,  
values greater than 2 PM. In earlier studies with S1 thymidine 
kinase we obtained similar results for the thymidine K,, but 
we had been unable to measure a Ki with acyclovir (22). 
The thymidine kinase induced by the  mutant  B3  had a X, 
for thymidine (0.3 PM) similar to  that of the wild type enzyme 
(0.2 p ~ ) .  However, the Kc for the analogue BVdU  was consid- 
erably higher (4.5 PM) than  that of the wild type enzyme (0.1 
PM), again indicating a decrease in affinity of the mutant 
enzyme for the drug, but in this case not associated with 
decreased affinity for the natural  substrate. 
In experiments using acyclovir or BVdU as inhibitors of 
thymidine phosphorylation inhibition appeared competitive, 
confirming the likely site of action of these analogues to be 
the thymidine binding site and suggesting that  they may act 
as  alternative substrates for the enzyme. This was confirmed 
directly using the radiolabeled drugs as  substrates  (Table 111). 
In these experiments it is probably only valid to compare the 
relative phosphorylating activities of each individual enzyme, 
comparisons between enzymes being considerably more diffl- 
cult in the absence of precise quantitative data on the  amount 
of each enzyme present in the assays. Thus, the wild type 
enzyme phosphorylated BVdU with greater efficiency than 
thymidine and acyclovir at  rather lower efficiency. B3 thy- 
midine kinase, in contrast, phosphorylated BVdU poorly, but 
acyclovir was phosphorylated in relative terms  as well as by 
the wild type enzyme. The poor phosphorylation of BVdU 
may explain why B3 is significantly more resistant to BVdU 
in tissue culture than SI, even though the K ,  values for BVdU 
of both S1 and B3 thymidine kinases are similarly elevated. 
Tr7 and SI thymidine kinases were similar to wild type 
enzyme in as much as they phosphorylated BVdU more 
efficiently than thymidine. However, there appeared to be no 
detectable phosphorylation of acyclovir by these mutant  thy- 
midine kinases. This was not surprising in view  of the reduced 
binding affinity of these enzymes for acyclovir (Fig. 3). These 
data suggest that there would be little phosphorylation of 
acyclovir in SI- and Tr7-infected cells compared with that in 
cells infected by the wild type virus. ___- "___ 
H. J. Field and B. A. Larder, unpublished results. 
Drug-resistant  Variants 
It is clear from the results that all three  mutant viruses 
express enzymes with impaired ability to phosphorylate the 
drugs used in their selection. It is difficult to know whether 
the differences are sufficient to account for the observed 
resistance of these viruses to  the drugs, but in the absence of 
any apparent changes in DNA polymerase this would seem 
the most likely explanation. 
Thus, in conclusion, we have shown that drug-resistant 
viruses may retain a TK+ phenotype (thus retaining patho- 
genicity) but induce altered thymidine kinases which show 
lower affinity for nucleoside analogue substrates  than  the wild 
type enzyme. This c o n f i i s  our earlier work with S1 but 
shows that  this is not  a  unique phenomenon. Like S1, Tr7 is 
an acyclovir-resistant mutant, but its thymidine kinase has 
properties which clearly distinguish it from S1 thymidine 
kinase. In addition, this  type of response is not  restricted  to 
acyclovir but may also be  seen in mutants resistant to BVdU. 
We would suggest that  this is a general strategy which may 
be adopted by HSV to confer resistance to those nucleoside 
analogues which require initial phosphorylation by  HSV thy- 
midine kinase, and that adoption of this strategy may not 
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